Pharmafile Logo
Pharmafocus logo
Advanced Search

InterMune

Showing 13 posts of 13 posts found.

Ofev image

Boehringer gains EU approval for Ofev

January 19, 2015
Sales and Marketing Boehringer, Esbriet, IPF, InterMune, ingelheim, nintedanib, ofev

The European Commission has approved Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis (IPF). The approval follows the …

News
Roche image

Roche buys Ariosa Diagnostics

December 2, 2014
Research and Development, Sales and Marketing IPF, IQuum, InterMune, Roche, ariosa, cfdna, diabetes, genia, seragon

Roche has purchased the privately-held US company Ariosa Diagnostics for an undisclosed fee as it looks to expand further into …

News
Boehringer image

Boehringer and Roche IPF drugs win FDA approval

October 16, 2014
Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, FDA, IPF, InterMune, Roche, US, lung scarring, lungs, ofev

The FDA has approved both Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of the fatal lung …

News
ERS event image

InterMune’s IPF drug shines at ERS Congress

September 10, 2014
Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, IPF, InterMune, idiopathic pulmonary fibrosis, munich, pirfenidone

InterMune has posted positive data for its lung-scarring drug at this year’s European Respiratory Society Annual Congress 2014 (ERS). Pharmafile …

News
roche_glass_building

Roche pays $8.3bn for InterMune

August 26, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Genentech, IPF, Illumina, InterMune, Roche

Roche has stumped up $8.3 billion in cash to pay for US biotech firm InterMune and will gain access to …

News
InterMune image

InterMune stock jumps on suitor claims

August 14, 2014
Sales and Marketing Boehringer, Esbriet, FDA, GSK, IPF, InterMune

Riding high of the success of its new lung drug Esbriet, InterMune has become the focus of some serious takeover …

News
Esbriet image

Shortlist announced for best new pharma product

June 24, 2014
Research and Development, Sales and Marketing Esbriet, InterMune, Lemtrada, Orphan, dificlir, innovative, pif, prix galion, selincro

Treatments for idiopathic pulmonary fibrosis, hepatic encephalopathy and meningococcal infection are among 14 new medicines shortlisted for the UK Prix …

News
Esbriet image

InterMune drops EMA lawsuit over data release

June 10, 2014
Research and Development, Sales and Marketing EMA, EU, Esbriet, Goldacre, InterMune, alltrials, lung

InterMune has ended a year-long legal spat with the European Medicines Agency over the potential release of data for its …

News

Boehringer and InterMune data on IPF drugs impress

May 19, 2014
Research and Development, Sales and Marketing Boehringer Ingelheim, InterMune, idiopathic pulmonary fibrosis

Two new medicines for a generally fatal lung disease, known as idiopathic pulmonary fibrosis and made by Boehringer and InterMune, …

News
ema_building_face_web

EMA transparency agenda sees more delay

April 9, 2014
Medical Communications, Sales and Marketing AbbVie, EFPIA, EMA, Europe, InterMune, alltrials, parliament, transparency

The European Medicines Agency is to further delay its policy over clinical trial transparency, saying it needs more time to …

News
Esbriet image

InterMune scores in lung trial

February 26, 2014
Research and Development, Sales and Marketing Esbriet, FDA, IPF, InterMune, fvc, lung

InterMune has taken another step on its lengthy road to get the US regulator to approve its drug Esbriet for …

News
EMA image

Court annuls EMA data decision

December 5, 2013
Medical Communications, Sales and Marketing AbbVie, EMA, Goldacre, InterMune, alltrials, transparency

The European Court of Justice has annulled interim injunctions against the European Medicines Agency issued earlier this year after AbbVie …

News

First idiopathic pulmonary fibrosis drug approved

March 4, 2011
Sales and Marketing Esbriet, IPF, InterMune, Orphan Drugs, idiopathic pulmonary fibrosis, orphan drug

The first ever treatment for the potentially fatal lung disease idiopathic pulmonary fibrosis (IPF) has been approved in the EU. …

News

Latest content

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023

Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment

December 6, 2023

British Medical Journal publishes letter calling on government to reduce rate of antidepressant prescribing

December 5, 2023

Genentech shares positive results from phase 3 trial for breast cancer treatment

December 5, 2023

Dr Stefano Gulià appointed as chief scientific officer of Kling Bio

December 5, 2023